These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35576644)

  • 1. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis.
    Julià A; Gómez A; López-Lasanta M; Blanco F; Erra A; Fernández-Nebro A; Mas AJ; Pérez-García C; Vivar MLG; Sánchez-Fernández S; Alperi-López M; Sanmartí R; Ortiz AM; Fernandez-Cid CM; Díaz-Torné C; Moreno E; Li T; Martínez-Mateu SH; Absher DM; Myers RM; Molina JT; Marsal S
    EBioMedicine; 2022 Jun; 80():104053. PubMed ID: 35576644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis.
    Luque-Tévar M; Perez-Sanchez C; Patiño-Trives AM; Barbarroja N; Arias de la Rosa I; Abalos-Aguilera MC; Marin-Sanz JA; Ruiz-Vilchez D; Ortega-Castro R; Font P; Lopez-Medina C; Romero-Gomez M; Rodriguez-Escalera C; Perez-Venegas J; Ruiz-Montesinos MD; Dominguez C; Romero-Barco C; Fernandez-Nebro A; Mena-Vazquez N; Marenco JL; Uceda-Montañez J; Toledo-Coello MD; Aguirre MA; Escudero-Contreras A; Collantes-Estevez E; Lopez-Pedrera C
    Front Immunol; 2021; 12():631662. PubMed ID: 33833756
    [No Abstract]   [Full Text] [Related]  

  • 3. A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
    Aterido A; Cañete JD; Tornero J; Blanco F; Fernández-Gutierrez B; Pérez C; Alperi-López M; Olivè A; Corominas H; Martínez-Taboada V; González I; Fernández-Nebro A; Erra A; López-Lasanta M; López Corbeto M; Palau N; Marsal S; Julià A
    Front Immunol; 2019; 10():1459. PubMed ID: 31312201
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for
    Spiliopoulou A; Colombo M; Plant D; Nair N; Cui J; Coenen MJ; Ikari K; Yamanaka H; Saevarsdottir S; Padyukov L; Bridges SL; Kimberly RP; Okada Y; van Riel PLC; Wolbink G; van der Horst-Bruinsma IE; de Vries N; Tak PP; Ohmura K; Canhão H; Guchelaar HJ; Huizinga TW; Criswell LA; Raychaudhuri S; Weinblatt ME; Wilson AG; Mariette X; Isaacs JD; Morgan AW; Pitzalis C; Barton A; McKeigue P
    Ann Rheum Dis; 2019 Aug; 78(8):1055-1061. PubMed ID: 31036624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.
    Iwasaki T; Watanabe R; Ito H; Fujii T; Okuma K; Oku T; Hirayama Y; Ohmura K; Murata K; Murakami K; Yoshitomi H; Tanaka M; Matsuda S; Matsuda F; Morinobu A; Hashimoto M
    Front Immunol; 2022; 13():901437. PubMed ID: 35734167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy.
    Wright HL; Thomas HB; Moots RJ; Edwards SW
    Rheumatology (Oxford); 2015 Jan; 54(1):188-93. PubMed ID: 25125592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study.
    Daien CI; Gailhac S; Mura T; Combe B; Hahne M; Morel J
    Arthritis Res Ther; 2014 Apr; 16(2):R95. PubMed ID: 24735586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs.
    Zhao J; Ye X; Zhang Z
    Clin Rheumatol; 2020 Sep; 39(9):2573-2581. PubMed ID: 32206975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD; Baker JF; Ogdie A
    J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
    Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
    Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis.
    Strand V; Zhang L; Arnaud A; Connolly-Strong E; Asgarian S; Withers JB
    Expert Opin Biol Ther; 2022 Jun; 22(6):801-807. PubMed ID: 35442122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy.
    Sutcliffe M; Nair N; Oliver J; Morgan AW; Isaacs JD; Wilson AG; Verstappen SMM; Viatte S; Hyrich KL; Morris AP; Barton A; Plant D
    Rheumatology (Oxford); 2022 Nov; 61(12):4935-4944. PubMed ID: 35377444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
    Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
    Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.
    Nakayama Y; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A; Hashimoto M
    Rheumatol Int; 2022 Jul; 42(7):1227-1234. PubMed ID: 35266034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study.
    Jiang X; Askling J; Saevarsdottir S; Padyukov L; Alfredsson L; Viatte S; Frisell T
    Arthritis Res Ther; 2016 Dec; 18(1):288. PubMed ID: 27912794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.